Association for Research in Vision and Ophthalmology

Association for Research in Vision and Ophthalmology

Issue: July 2012
May 08, 2012
1 min read
Save

Study: Ocriplasmin treatment closed full-thickness macular holes in some patients

Issue: July 2012
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

FORT LAUDERDALE, Fla. — A single-dose injection of ocriplasmin was able to close full-thickness macular holes in 41% of patients, according to a subgroup analysis of the MIVI-TRUST phase 3 clinical trial presented here.

Dante J. Pieramici, MD, and David S. Boyer, MD, presented results of the subgroup analysis in a poster presentation at the Association for Research in Vision and Ophthalmology meeting.

In the study, 106 eyes with a full-thickness macular hole were randomized to receive a 125-µg injection of ocriplasmin (ThromboGenics) and 47 eyes received placebo.

"At day 28, 40.6% of ocriplasmin-treated eyes demonstrated nonsurgical full-thickness macular hole closure as compared to 10.6% of placebo-treated eyes," the authors said in the poster. At 6 months, the same percentage of macular holes remained closed.

Patients tolerated treatment well, and ocriplasmin did not interfere with vitrectomy results in closing remaining macular holes, according to the poster.

  • Disclosure: Dr. Pieramici Boyer receives financial support, is a consultant with and receives other reimbursements from Genentech and Thrombogenics; receives financial support from Regeneron ; and is a consultant with and receives other reimbursements from Alimera. Dr. Boyer receives financial support, is a consultant with and receives other reimbursements from Alcon, Allergan, Genentech and Regeneron. He is a consultant with Allegro, Neurotech and Novartis/QLT. He receives financial support from iCo. He receivers other reimbursements from Novartis and Pfizer.